Discovery Europe 2024

22 - 23 May 2024 | Basel, Switzerland

Together with Neuroscience Drug Development Europe, attendees especially benefit from a 2-day event addressing emerging strategies for the drug development of neuroscience.

Event Page - Hero Banner 5
Overview Drug Discovery Summit & Discovery Chemistry Europe Neuroscience Drug Development Europe
+co-located event:
Automate Europe 2024

Explore Discovery Europe 2024: Unlocking Future Insights in Advancing Drug Discovery Pipelines & Research 

Discovery Europe 2024 features the co-location of 22nd Annual Drug Discovery Summit & Discovery Chemistry Europe and the 5th Annual Neuroscience Drug Development Europe Congresses.

Join and network with over 350 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation and HIT optimisation of small and large molecule drugs. The Drug Design & Medicinal Chemistry focused event also offer insightful innovations in Automation And Synthesis In Organic Chemistry as well as Molecular Drug Design.

Together with Neuroscience Drug Development Europe, attendees especially benefit from a 2-day event addressing emerging strategies for the drug development of neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative diseases.

22nd Annual Drug Discovery Summit & Discovery Chemistry Europe Congress

Join and network with over 230 industry leaders at the renowned Drug Discovery Summit in Basel, where we will address the latest advancements in target identification, validation and HIT optimisation. The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics - based discovery, Organ-on-a-chip and 3D modelling. Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation.

  • The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.
  • Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation.
  • Join our 2-day innovation showcase situated alongside the main programme, which aims to inspire growth and create collaboration opportunities for all who attend.

Agenda at a Glance

  • Workshop 1: Organ Modelling
  • Workshop 2: Targeted Protein Degradation
  • Workshop 3: Automation or AI in Medicinal Chemistry and Drug Design

Drug Discovery Summit

  • Day One | Track 1: Identification And Validation Of Novel Targets For Next Generation Therapeutics
  • Day One | Track 2: Animal And Disease Modelling, Organoid And Organ On The Chip Based Discovery
  • Day One | Track 3: Discovery on Target – Screening and Genomic Strategies
  • Day Two | Track 1: Phenotypic & Target Based Discovery Approaches

Drug Design & Medicinal Chemistry Summit

  • Day One | Track 1: Computational Drug Design: AI In Chemical Synthesis, Target ID Capabilities, Lead Identification, Lead Optimisation, Measuring PK/PD & Prediction
  • Day Two | Track 2: Hit Finding Technologies And Advancements
  • Day Two | Track 3, Part 1: Automation And Synthesis In Organic Chemistry
  • Day Two | Track 3, Part 2: Molecular Drug Design And Med Chem: Innovations In Fragment & Structured Based Drug Discovery

5th Annual Neuroscience Drug Development Europe Congress

A thorough, 2-day event addressing emerging strategies for the drug development of neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative diseases.

  • Examine the latest advancements and emerging trends in developing neurological treatments, including targeted approaches and novel strategies.
  • Discuss the pioneering innovations in stem cell technologies, with the latest updates on iPS cells for disease modelling and drug discovery. 
  • Establish in-depth knowledge of cutting-edge recent advances in gene therapy for CNS drug discovery and current opportunities for digital biomarkers in neuroscience.

Agenda at a Glance

Day One | Track 1: Therapeutic Strategies, Enabling Technologies & Biomarker Development

Day Two | Track 1: Drug Discovery For Neurodegenerative Disease

3rd Annual SmartLabs Automation & Robotics Congress

Attendees of Discovery Europe 2024 also have access to Automate Europe 2024

Explore Automate Europe 2024: Unlocking Future Insights in Automation & Robotics Research and Development  

Automate 2024 consists of the 3rd Annual SmartLabs Automation & Robotics Congress, at which visionary leaders will discuss the current state of the industry, market trends and future growth areas pushing the pharma automation industry in the future. Join leaders, experts and researchers and discuss digital QA/QC labs, accelerating digital transformation, lab robotics & tools for drug discovery workflows, robotic process automation and implementing AI/ML in the lab. Automation of pharma manufacturing and the application of mobile robotics in QA/QC labs will also be discussed.

  • The 2-day programme features the innovation and advancement in mobile robot technology and applications, and competitive advantages that can be gained in drug development and pharma manufacturing, automation and logistics.
  • Learn about key focus areas in developments in the automation & digitisation of QA/QC labs, accelerating digital transformation, lab robotics & tools for drug discovery workflows, robotic, process automation and implementing AI/ML in the lab.

Agenda at a Glance

  • Day One | Track 1: Bridging The Gap Between Automation & Digitalisation through FAIR & Digital Transformation 
  • Day One | Track 2: Smart Manufacturing & Digitisation Optimisation
  • Day One | Track 3: Mobile Robotics In R&D Laboratories
  • Day Two | Track 1: Automation with AI/ML & Robotics Tools in Drug Discovery & Development 
  • Day Two | Track 2: Data-Driven Modelling & Data Analytics for Drug Discovery & Development 


Good number of 1-1 meetings with relevant people. Very happy with the networking process and the Oxford Global team are very nice and service minded.

Regional Sales Director



Absolutely outstanding conference attracting large pharma and aspiring biotechs. Oxford Global are excellent, the food is outstanding and the preset meetings are informal and impactful

Vice President of Business Development

Novalix Logo


The organisation was perfect. Good mix between excellent scientific presentations and network opportunities.

Pharmacology Associate Director



This was my first time at the conference and it was a great experience. Very well organized conference and I learned a lot and made valuable connection - Thank you Oxford Global.

Senior Principal Scientist


What to Expect


leading pharma, biotech & academic delegates

hours of presentations, discussions & interactive content
hours of networking breaks, including speed networking & refreshments
pre-arranged 1-2-1 meetings, facilitating business growth
What to Expect Engaging Thought Leadership
What to Expect Global Technological Showcase
What to Expect Networking Emphasis
What to Expect Innovative Poster Displays

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 100 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

Companies Represented Include

Biotech Innovation & Collaboration

Inspiring Tomorrow's Breakthroughs: Unleashing Innovation & Collaboration in Discovery Research & Development

Join engaging presentations featured in our innovation and collaboration track running across day 2 and 3, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.  

The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biomarkers discovery & development.

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:  

  • Seeking collaboration partners with pharma and solution providers 
  • Discovering new investment opportunities with pharma 
  • Learning about the latest industry trends & challenges  
  • Keeping updated with new innovations and technology solutions 
  • Showcasing their company profile to a targeted and engaged audience

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The Discovery Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist. 

Please submit your poster presentation by no later than 20th December 2024 in the below category: 

  • Emerging Technologies  
  • Biomarkers in Therapeutics  
  • Biomarkers in Diagnostics  
  • Biomarkers in Clinical Trials & Precision Medicine  
  • Omics-Based Biomarker Discovery
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 20th December 2024
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 20th December 2024 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the Biomarkers series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

For further information contact

Meet Our Expert Speakers

Discovery Europe 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Berengere Dumotierd
Associate Director,
Davide Gianni
Senior Director,
Geoffrey Kerchner
Vice President,
F. Hoffmann-La Roche, Ltd.
Irene Choi
Head of Drug Discovery,
Verge Genomics
Janet Brownlees
Senior Director,
Merck Sharpe and Dohme
Johan Luthman
Executive Vice President of Research & Development,
Nils Hansen
Chief Executive Officer,
Oliver Hucke
Associate Director,
Boehringer Ingelheim
Sanne Glad
Scientific Director,
Amgen Research Copenhagen
Simona Cotesta

All Speakers

Amelie Joffrin
Anna Vulpetti
Associate Directir,
Anto Pavlovic
Principal Research Associate,
Hoffmann La Roche Ltd
Arianna Sabò
Head of Research & Development,
QUANTRO Therapeutics
Ashutosh Dhingra
Staff Scientist,
German Center for Neurodegenerative Diseases
Borislav Dejanovic
Senior Director,
Vigil Neuroscience
Carl Poelking
Associate Director,
CB Gurumurthy
Professor and Director,
University of Nebraska Medical Center
Daohong Zhou
David Bearss
Chief Executive Officer,
Halia Therapeutics
Diana Zindel
Associate Director,
Eileen Wegner
Research Associate,
NMI Naturwissenschaftliches und Medizinisches Institut
Emma Davies
Associate Director - Preclinical,
Eric Goedken
Senior Principal Scientist,
Filip Roudnicky
Senior Principal Scientist,
Gebhard Thoma
Associate Director,
Gergely Toth
Chief Executive Officer & Chief Scientific Officer,
Cantabio Pharmaceuticals
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
Graham Dempsey
Chief Scientific Officer,
Quiver Bioscience
Gregori Gerebtzoff
Hai Rao
Professor and Chair of Biochemistry,
Southern University of Science and Technology
James Overell
Group Medical Director,
Jon Lea
Team Leader,
Jonathan Mason
Senior Research Advisor,
Design for Drug Discovery
Jose Luis Molinuevo
Vice President Head of Experimental Medicine,
H. Lundbeck A/S
Julian Röwe
Senior Scientist,
Kerstin Hofer
Senior Scientist,
Manuel Stritt
Head Scientific Computing Drug Discovery,
Idorsia Pharmaceuticals
Markus Schade
Principal Scientist,
Morten Grunnet
Vice President, Head of Neuroscience and Professor,
H. Lundbeck A/S
Nathalie Cartier-Lacave
Senior Vice President Neurobiology,
Olivier Loiseleur
Senior Team Leader,
Olivier Kitten
Founder and Chief Executive Officer,
Olivier Bugaud
Senior Scientist Assay Development & Technologies,
Paulina Kolasinska-Zwierz
Principal Scientist,
Peter Brandt
Head of Chemistry,
Beactica Therapeutics AB
Prashant Gahtori
Graphic Era Hill University
Richard Lewis
Robert Fremeau
Chief Executive Officer,
BrainStorm Therapeutics, Inc
Robin Loving
Chief Scientific Officer,
Salipro Biotech AB
Simon Huet
Senior Scientist,
Takhar Kasumov
Associate Professor,
Northeastern Ohio University
Ulrike Künzel
Associate Principal Scientist,
Urs Langen
Laboratory Head,
Xinxin Gao
Principal Scientific Manager,

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

New Trailblazer Profluent Launches its AI-enabled OpenCRISPR-1 to Edit the Human Genome

Profluent successfully combined large language models (LLMs) and CRISPR for an open-source AI gene editing project which could reshape CRISPR treatment options.

Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments

Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles.

From Screening to Success: How Molecular 'Super-Glue' SJ3149, Could Advance Cancer Treatments

Researchers at St Jude Children's Research Hospital used high throughput screening (HTS) to identify SJ3149, a molecular glue degrader. This small molecule demonstrated efficacy across a range of cancer types.

Novo Nordisk Foundation and NVIDIA to Launch a State-of-the-Art National AI Research Centre

Novo Nordisk and NVIDIA join forces to build an AI supercomputer which will be housed in Denmark's national centre for AI innovation.

AI-driven High Throughput Screening for Targeted Drug Discovery

Artificial Intelligence (AI) has significantly transformed high throughput screening (HTS) in drug discovery, increasing efficiency, accuracy, and predictive capabilities in early drug development stages. This research highlights AI's integration into HTS processes, showcasing improved outcomes in hit identification, assay optimization, and target validation, thus accelerating and refining the search for new medications.

Post-Event Proceedings – Discovery Europe 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Discovery Europe 2023.

Plan Your Visit

Congress Center Basel
MCH Swiss Exhibition (Basel) Ltd. Messeplatz 21, CH-4058 Basell

By Rail

Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)

By Tram

From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.

By Air

EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit:

By Car

Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.

We have sold out of our contracted bedrooms for this event. Please see nearby accommodation options for rates and availability here.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery Europe 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch